Research

Steven W. Millward, Ph.D. is developing a research program focusing on the directed evolution of molecular imaging agents and therapeutics for the diagnosis and treatment of cancer. Funded research projects include:

SUPR Peptides for Targeted Radionuclide Delivery
HHSN261201500072C                                      Millward, Fiacco (PIs)                                09/22/15-10/20/16
EvoRx Technologies, Inc. - NCI Phase I SBIR Contract
Major Goal: Validate the use of Her2-targeting SUPR peptides for the delivery of radiotherapy to tumors.
Role: Principal Investigator

SUPR Peptides for Immune Checkpoint Blockade Imaging
CABI/G.E. In-Kind Research Award          Millward, Roberts (PIs)                            07/01/16-06/30/21
Multi- Investigator Imaging (MI2) Research Award
Major Goal: Develop a SUPR peptide-based PET tracer for PD-L1 imaging and prediction of response to PD-1/PD-L1 therapies.
Role: Principal Investigator

Targeted Molecular Imaging of Cell Death in Ovarian Cancer
1R21CA181994-01A1                                       Millward, Lu (PIs)                                       02/03/16-01/31/18
NCI Exploratory/Developmental Research Grant Award
Major Goal: Develop targeted molecular imaging agents to visualize apoptosis and autophagy in vivo by PET and MRI.
Role: Principal Investigator

Development of SUPR peptides as PET Imaging Agents for Her2-positive Breast Cancer
2R44CA206771-02                                            Millward, Fiacco (PIs)                                  5/06/16-04/30/18
EvoRX Technologies, Inc. - NCI Phase II SBIR Contract
Major Goal: Carry out preclinical evaluation of a SUPR peptide-based PET radiotracer for visualization of Her2 expression in breast cancer.
Role: Principal Investigator

Passenger Deletion of ENO1 as a Targetable Vulnerability in Cancer
128307-RSG-15-145-01-CDD                        Muller (PI)                                                     01/01/16-12/31/19
American Cancer Society Research Scholar Award
Major Goal: Probe the biochemical consequences, adaptations and possible bypasses of Enolase inhibition in vitro as well as directly validate ENO1 deletion as a therapeutic target in intracranial gliomas in vivo, and finally, to identify a clinical candidate Enolase inhibitor.
Role: Co-Investigator

Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology
1T32CA196561-01                                             Sokolov (PI)                                                  09/01/15-08/31/20
NIH/NCI
Major Goal:  to enhance the education of the next generation of young scientists in biomedical imaging research using nanotechnologies by combining training in fundamental aspects of nanoscience and nanotechnology with clinical questions faced in cancer imaging and therapy.
Role: Mentor